Last reviewed · How we verify
Perycit (NICERITROL)
Perycit (generic name: NICERITROL) is a niceritrol drug. It is currently in Phase 2 development.
Perycit is thought to work by interacting with cellular targets to produce a therapeutic effect.
Perycit, also known as NICERITROL, is a small molecule drug in the niceritrol class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Perycit is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety and efficacy. As a result, Perycit is not currently available for clinical use.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NICERITROL |
|---|---|
| Drug class | niceritrol |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a orchestra, and Perycit is like a conductor that helps the cells work together to produce a specific outcome. However, the exact way it conducts the cells is not yet fully understood. More research is needed to determine how Perycit produces its effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perycit CI brief — competitive landscape report
- Perycit updates RSS · CI watch RSS
Frequently asked questions about Perycit
What is Perycit?
How does Perycit work?
What is the generic name of Perycit?
What drug class is Perycit in?
What development phase is Perycit in?
Related
- Drug class: All niceritrol drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing